Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: A review

Cancer Treatment Reviews

Volumn 29, Issue 1, 2003, Pages 11-19

  Nieder, C ^a   Licht, T ^a   Andratschke, N ^a   Peschel, C ^a   Molls, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Diffuse large cell lymphoma; Non Hodgkin's lymphoma; Radiotherapy; Therapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GALLIUM 67; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; VINCRISTINE;

ADVANCED CANCER; B CELL LYMPHOMA; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CELL COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; LARGE CELL LYMPHOMA; LUNG TOXICITY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RADIATION HAZARD; RETROSPECTIVE STUDY; REVIEW; SALIVARY GLAND; SCINTISCANNING; TUMOR CELL; TUMOR VOLUME;

EID: 0037303501     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00094-4     Document Type: Review

References (35)

1. Tsang RW, Gospodarowicz MK, O'Sullivan B. Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 2002; 52: 643-651.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma: the international Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-999.
3. Kaminski MS, Coleman N, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Int Med 1986; 104: 747-756.
4. Tsang RW, Gospodarowicz MK. Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol 2001; 80(Suppl 3) B66-72.
5. Van der Maazen RW, Noordijk EM, Thomas J, Raemaekers JM, Meerwaldt JH. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphoma. Radiother Oncol 1998; 49:1-7.
6. Zinzani PL, Stefoni V, Tani M, et al. MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leuk Lymphoma 2001; 42: 989-995.
7. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
8. Glick JH, Kim KJ, Earle J, et al. An ECOG randomised phase III trial of CHOP versus CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma (Abstract). Proc Am Soc Clin Oncol 1995; 14: 391.
9. Aviles A, Delgado S, Ruiz H, De la Torre A, Guzman R, Talavera A. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer, Oral Oncol B 1996; 32: 19-23.
10. Oguchi M, Ikeda H, Isobe K, et al. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 2000; 48: 161-168.
11. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002; 20: 197-204.
12. Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van't Veer MB. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol 2001; 58: 252-255.
13. Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 720-725.
14. Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial (Abstract). Ann Hematol 2001; 80: B154-155.
15. Fuller LM, Krasin MJ, Velasquez WS, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys 1995; 31: 3-11.
16. Kamath SS, Marcus RB, Lynch JW, Price Mendenhall N. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 563-568.
17. Wilder RG, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001; 49: 17-22.
18. Wilder RB, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, Cox JD. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer 2002; 94: 601-605.
19. Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 2001; 50: 743-749.
20. Fisher RI. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Semin Oncol 2000; 27(Suppl 12): 2-8.
21. Velasquez W, Fuller LM, Oh KK, et al. Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas. Cancer 1984; 53: 1478-1483.
22. Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz MJ. Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 1994; 30: 799-803.
23. Schlernbach PJ, Wilder RB, Tucker SL, et al. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 2000; 48: 1107-1110.
24. Shipp MA, Klatt MM, Yeap B, et al. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol 1989; 7: 613-618.
25. Coiffier B. Treatment of aggressive non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 12-20.
26. Ferreri AJ, Dell'Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B-cell lymphomas. Oncology 2000; 58: 219-226.
27. Rube C, Nguyen TP, Kloss M, Loeffler M, Trumper L, Pfreundschuh M. Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Hematol 2001; 80(Suppl 3): B84-85.
28. Krieger G, Kreysing E, Kneba M. Long-term results with MACOP-B and radiation therapy for aggressive lymphomas (German). Onkologie 2001; 24(Suppl 1): 49-58.
29. Bartlett NL, Kwak LW, Horning SJ. MACOP-B ± radiation therapy for diffuse large cell lymphoma. Cancer 1993; 71: 4034-4042.
30. Schmits R, Glass B, Trumper L, Pfreundschuh M. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL. Ann Hematol 2001; 80(Suppl 3): B77-83.
31. Ulusakarya A, Lumbroso J, Casiraghi O, et al. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35: 579-586.
32. 67Gallium scan in 50 patients. Blood 1999; 94: 3289-3293.
33. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma 2000; 39: 543-553.
34. Harris N, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
35. Harris N, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.